The efficacy of immune checkpoint blockade with antibodies that target the programmed cell death protein 1 pathway (PD‐1/PD‐L1) and cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4) have been reported in a variety of malignancies 40. This evidence concerns the gene PDCD1 and cancer.